Microbix makes biotherapeutic drugs, vaccines, and infectious disease diagnostics for multinational manufacturers. The company's pipeline includes leading generic drug candidate ThromboClear for the treatment of coronary artery thrombosis and the FDA-approved drug urokinase, used to treat pulmonary embolism. Microbix has also submitted patents for its Sperm Sexing Technology, which enables livestock producers to predetermine offspring gender prior to conception. In 2008 Microbix entered into an agreement with China to build one of the world's largest influenza manufacturing plants to produce flu vaccines.

AstraZeneca Pharmaceuticals LP company, a subsidiary of global druggernaut AstraZeneca, is the fifth-largest drug company in the US. Its sales represent about 5% of all the drugs sold in the US and 45% of its parent company's revenues. AstraZeneca US' treatments focus on several therapeutic areas: cardiovascular and metabolic, gastrointestinal, infection, neuroscience, oncology, and respiratory. Its best-known products include Nexium (acid reflux), Seroquel (anti-psychotic), Crestor (high cholesterol), and Arimidex (breast cancer treatment).

WuXi PharmaTech (Cayman) Inc. (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the R&D process to its customers, which include pharmaceutical, biotechnology and medical device companies. The Company operates in two segments: laboratory services and manufacturing. Laboratory services for pharmaceutical, biotechnology and medical device companies. Manufacturing segment services for producing advanced intermediates and active pharmaceutical ingredients for use by pharmaceutical companies in preclinical and clinical trials. In January 2008, the Company completed its acquisition of AppTec Laboratory Services, Inc.

Matrixx Initiatives, Inc., through its subsidiaries, engages in the development, production, marketing, and sale of over-the-counter (OTC) healthcare products. It offers Zicam Cold Remedy nasal pump, a homeopathic nasal gel that reduces the duration and severity of the common cold; Zicam Cold Remedy Swabs for consumers, who dislike nasal sprays; and Zicam Cold Remedy Chewables, Zicam Cold Remedy RapidMelts, Zicam Cold Remedy Oral Mist, Zicam Cold Remedy RapidMelts + Vitamin C, and Zicam Cold Remedy RapidMelts + Vitamin C and Echinacea, which are oral cold remedy products that deliver a dose of ionic zinc to the oral mucosa. The company also provides Zicam Allergy Relief, a homeopathic nasal gel formula to control allergy symptoms for sufferers of hay fever and upper respiratory allergies; Zicam Extreme Congestion Relief, a nasal gel for relief of nasal congestion and sinus pressure; and Zicam Sinus Relief that provides the benefit of the product with the aromatic strength of a cooling menthol/eucalyptus blend. In addition, it offers Zicam Cough Spray products to deliver cough relief and soothe throat irritation, including Zicam Cough Max, a liquid spray formulation that provides relief. Further, the company offers Zicam Multi-Symptom Cold and Flu Relief products, which utilize a spoon dosing delivery to provide relief of cold and flu symptoms; and Xcid, a creamy antacid product. It sells products directly to food, drug, mass market, and wholesale warehouse retailers in the United States, as well as to distributors that sell to retail establishments under the Zicam, Nasal Comfort, and Xcid brands.

DUSA Pharmaceuticals, Inc. was founded in 1991 and is based in Wilmington, Massachusetts. DUSA Pharmaceuticals, Inc., an integrated dermatology pharmaceutical company, develops and markets Levulan photodynamic therapy (PDT) and other products for common skin conditions in the United States and internationally. Its products include Levulan Kerastick 20% Topical Solution with PDT and the BLU-U brand light source for the treatment of non-hyperkeratotic actinic keratoses of the face or scalp. The BLU-U is used without Levulan to treat moderate inflammatory acne vulgaris and general dermatological conditions. The company is also developing non-PDT drug products, including Nicomide, Nicomide-T, AVAR products, ClindaReach, Meted, and Psoriacap products.

Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

Pfizer Limited company is the top provider of medicines to the UK's National Health Service, offering many of its parent company's products to treat conditions including cardiovascular ailments and cancers. It also provides animal health products. Pfizer Limited conducts research and development activities, focusing on medications in the areas of allergy, respiratory, urinary, metabolic, and gastrointestinal ailments, as well as vaccines, anti-retrovirals, and pain treatments.

Amicus Therapeutics, Inc. company was founded in 2002 and is based in Cranbury, New Jersey. Amicus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The Company’s products in development are Amigal (migalastat hydrochloride) for Fabry disease, Plicera (isofagomine tartrate) for Gaucher disease and AT2220 (1-deoxynojirimycin HCl) for Pompe disease. The Company completed its Phase II clinical trials of Amigal and are conducting Phase II clinical trials of Plicera and AT2220.

Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.